Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendrimer-based nanosized MRI contrast agents.

Hisataka Kobayashi1, Martin W Brechbiel

  • 1Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bldg. 10, Room B3B69, MCS 1002, 10 Center Dr., Bethesda, MD 20892-1002, USA. Kobayash@mail.nih.gov

Current Pharmaceutical Biotechnology
|December 8, 2004
PubMed
Summary

Researchers developed novel dendrimer-based MRI contrast agents (CAs) using Gadolinium. Varying molecular size and properties allows targeted excretion for renal, blood pool, liver, and lymphatic imaging, with potential for tumor-specific applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy.

Npj imaging·2026
Same author

Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer.

BMC cancer·2026
Same author

Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Understanding tumor microenvironment dynamics and immune checkpoint inhibitor efficacy following mEGFR-targeted near-infrared photoimmunotherapy.

Cancer letters·2026
Same author

Near-infrared Photoimmunotherapy Targeting High-risk Human Neuroblastoma Cells Expressing GD2.

Anticancer research·2025
Same author

Enhancement of drug delivery through fibroblast activation protein-targeted near-infrared photoimmunotherapy.

JCI insight·2025

Area of Science:

  • Biomedical Engineering
  • Radiology
  • Materials Science

Background:

  • Paramagnetic metals like Gadolinium shorten MRI T1 relaxation times.
  • Gadolinium-based MRI contrast agents (CAs) offer high sensitivity at low concentrations.
  • Macromolecular CAs are advantageous due to their diverse preparation and application potential.

Purpose of the Study:

  • To synthesize and characterize novel dendrimer-based macromolecular MRI CAs.
  • To investigate the influence of molecular size and properties on CA biodistribution and excretion.
  • To explore potential applications of these CAs in various imaging modalities.

Main Methods:

  • Synthesis of dendrimer-based macromolecular MRI CAs with varying sizes and hydrophilicity.
  • Characterization of CA properties including molecular weight, surface charge, and hydrophobicity.

Related Experiment Videos

  • In vivo studies to determine excretion routes (renal, liver) and accumulation in specific tissues (blood pool, lymphatics, tumors).

    • Main Results:

    • Dendrimer-based CAs exhibited spherical shape and consistent surface charges.
    • Smaller CAs (<60 kD) were renally excreted, suitable for functional renal imaging.
    • Larger, less hydrophilic CAs served as blood pool agents; hydrophobic variants accumulated in the liver.
    • Hydrophilic agents were useful for lymphatic imaging; antibody/avidin conjugates targeted tumors.

    Conclusions:

    • Dendrimer-based macromolecular CAs offer tunable properties for diverse MRI applications.
    • Molecular size and hydrophilicity are key determinants of CA biodistribution and excretion pathways.
    • Targeted CAs show promise for specific organ imaging, lymphatic imaging, and tumor-specific diagnosis and therapy.